Sentences with phrase «advanced lung cancer patients»

Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial

«What is particularly encouraging is that we are now able to select, based on features in the tumor, approximately a quarter of advanced lung cancer patients who can receive immunotherapy as their initial treatment.

Merck's cancer immunotherapy Keytruda is one of the pharma giant's rising stars, especially in the wake of evidence that the therapy had a survival benefit over standard chemotherapy in advanced lung cancer patients.

That's not just because of Opdivo's failure — last month, Keytruda was shown to be better than standard chemotherapy in untreated advanced lung cancer patients with high levels of the PD - L1 protein, both stopping cancer progression and extending patients» lives.

Not exact matches

The medicines, which help unleash the immune system on cancer cells, were tested in patients with advanced lung cancer.

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

For the new trial, hospitals enrolled patients with advanced, squamous non-small cell lung cancer whose disease had progressed despite initial chemotherapy.

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of thCancer: Results of lung cancer patients receiving (at least) 1 prior line of thcancer patients receiving (at least) 1 prior line of therapy.

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»

Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerllung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzecancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, SwitzerlLung Cancer Conference (ELCC) 2016 in Geneva, SwitzeCancer Conference (ELCC) 2016 in Geneva, Switzerland.

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

«Chemotherapy may be better for certain patients with advanced lung cancer.»

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

«Rapid advancements in genetic testing offer new treatment options for patients with advanced lung cancer.

The four - year study involved 461 patients at 24 medical oncology clinics at Princess Margaret Cancer Centre, University Health Network (UHN) with advanced lung, gastrointestinal, genitourinary, breast and gynecologic cancers.

In a study of 124 patients with advanced breast, lung, and prostate cancers, a new, high - intensity genomic sequencing approach detected circulating tumor DNA at a high rate.

The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.

Researchers enrolled 102 patients in with advanced non-small cell lung cancer in the phase 1b study to evaluate the durvalumab and tremelimumab combination therapy.

The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the gene HLung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the geneCancer that 24 of 920 patients (3 percent) with advanced - stage lung cancer had mutations in the gene Hlung cancer had mutations in the genecancer had mutations in the gene HER2.

«Our results suggest that administering p38 inhibitors to certain patients with advanced stages of colon cancer or with established metastases could be counterproductive and may enhance cell acquisition of lung colonization potential,» says Gomis.

ARandomized, Phase III, Double - Blind Placebo - Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum - Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer

A Phase 2 Study of MM - 121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to compare the effectiveness of daratumumab in combination with atezolizumab against atezolizumab alone in patients who have advanced non-small cell lung cancer (NSCLC) that has previously been treated.

An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types of cancer, the treatment shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney cancer, and 18 percent of patients with advanced non-small cell lung cancer.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single - arm trial.

While an earlier study had shown a similar immunotherapy drug to be effective for a significant proportion of patients with advanced melanoma or lung or kidney cancer, checkpoint inhibitors weren't making headway with colon cancer.

April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.

«The IASLC, being a global, multidisciplinary organization, is uniquely positioned to coordinate a harmonized strategy that can bring people together to show how the culture of lung cancer should reflect hope, as advances in lung cancer screening and early detection, personalized therapies, and immunotherapies are making a real impact in patients» lives.»

10/7/2008 Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccLung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vacclung cancer by treating patients with a novel kind of cancer vacancer by treating patients with a novel kind of cancer vacancer vaccine.

The primary goal of the campaign is to share the personal stories of those whose lives have been affected by lung cancer - including patients, caregivers, and advocates - while pointing to scientific advances that are enabling these patients to live longer and healthier lives.

Non-small cell lung cancer (NSCLC) accounts for roughly 85 % of lung cancer and most patients present with advanced disease at diagnosis.

IASLC would like to thank the patient advocacy organizations that have collaborated on this initiative: American Lung Association's LUNG FORCE, The Bonnie J. Addario Lung Cancer Foundation, Caring Ambassadors, Free ME From Lung Cancer, Free to Breathe, Global Resource for Advancing Cancer Education (GRACE), Live Lung, Lung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (patient advocacy organizations that have collaborated on this initiative: American Lung Association's LUNG FORCE, The Bonnie J. Addario Lung Cancer Foundation, Caring Ambassadors, Free ME From Lung Cancer, Free to Breathe, Global Resource for Advancing Cancer Education (GRACE), Live Lung, Lung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Association's LUNG FORCE, The Bonnie J. Addario Lung Cancer Foundation, Caring Ambassadors, Free ME From Lung Cancer, Free to Breathe, Global Resource for Advancing Cancer Education (GRACE), Live Lung, Lung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLUNG FORCE, The Bonnie J. Addario Lung Cancer Foundation, Caring Ambassadors, Free ME From Lung Cancer, Free to Breathe, Global Resource for Advancing Cancer Education (GRACE), Live Lung, Lung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer Foundation, Caring Ambassadors, Free ME From Lung Cancer, Free to Breathe, Global Resource for Advancing Cancer Education (GRACE), Live Lung, Lung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer, Free to Breathe, Global Resource for Advancing Cancer Education (GRACE), Live Lung, Lung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung, Lung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer Alliance, Lung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer Europe, Lung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer Foundation of America, Lung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer Initiative of North Carolina, Lung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer Research Foundation, Lungevity, Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (Patient Power, Rexanna's Foundation, University of Colorado Cancer Center, Upstage Lung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer, Women Against Lung Cancer in Europe (WALLung Cancer in Europe (WALCE).

Clinical responses in lung cancer patients have been impressive, with responses in patients with advance disease whose cancers did not respond to other treatment approaches.

The international early Phase II trial led by a team based at the Oxford Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this Cancer Research Centre will trial the experimental drug called LY2181308 with advanced non-small cell lung cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this cancer patients who no longer respond to platinum chemotherapy - the standard initial treatment for this group.

Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patients.

Combination of Advanced Lung Cancer Inflammation Index and C - Reactive Protein Is a Prognostic Factor in Patients With Operable Non-Small Cell Lung Cancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) pAdvanced Lung Cancer Inflammation Index and C - Reactive Protein Is a Prognostic Factor in Patients With Operable Non-Small Cell Lung Cancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patieLung Cancer Inflammation Index and C - Reactive Protein Is a Prognostic Factor in Patients With Operable Non-Small Cell Lung Cancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patCancer Inflammation Index and C - Reactive Protein Is a Prognostic Factor in Patients With Operable Non-Small Cell Lung Cancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) pPatients With Operable Non-Small Cell Lung Cancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patieLung Cancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patCancer Previous study of ours showed that advanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) padvanced lung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patielung cancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patcancer inflammation index (ALI) and C - reactive protein (CRP) are independent significant prognostic factors in operable non-small cell lung cancer (NSCLC) patielung cancer (NSCLC) patcancer (NSCLC) patientspatients.

In 2010, CRI researchers Drew Pardoll, M.D., Ph.D., Susan Topalian, M.D., and colleagues completed a phase I study showing that a PD -1-specific monoclonal antibody induces frequent tumor regressions in patients with advanced melanoma, renal cancer, lung cancer, and colon cancer with very low rates of toxicity.

This drug will be used for patients with metastatic or advanced lung cancer who did not respond to previous treatments.

Immunotherapy is a great advance in cancer treatment but up to a quarter of lung cancer patients are not eligible for this therapy.

In March, the U.S. Food and Drug Administration approved nivolumab for patients with advanced (metastatic) squamous non-small cell lung cancer.

This drug is indicated in combination with Cisplatin (a chemotherapeutic drug) for the first - line treatment of patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

Often, patients with advanced lung, breast, and prostate cancer develop this secondary cancerous invasion to the bone.